Dextromoramide (Tartrate)

Also known as: Dextrodiphenopyrine

Drug #227

Dextromoramide (Tartrate) is a narcotic analgesic (reliefes the pain with unconsciousness) and used in the management of severe chronic pain in terminal disease.

← Previous drug Next drug →

Primary Characteristics

Dextromoramide (Tartrate) is also known as Dextrodiphenopyrine.

It is of Synthetic origin and belongs to Opioid.

It belongs to OPIATE agonist pharmacological group on the basis of mechanism of action and also classified in Analgesic pharmacological group.

Molecular Weight: 542.6 · pK_a: 7.1 · Solubility in Water: 1 in 25 · Solubility in Alcohol: 1 in 85 · Non-proprietary name: Dextromoramide (Tartrate).

Molecular structure of Dextromoramide (Tartrate)

Pharmacokinetics

Distribution: Dextromoramide (Tartrate) has a volume of distribution is low. plasma protein binding is high.

Elimination: it is metabolised via partly, renal excretion is major.

Indications

Dextromoramide (Tartrate) is primarily indicated in conditions like Moderate to severe pain, Neuroleptanalgesia.

Contraindications

Dextromoramide (Tartrate) is contraindicated in conditions like Obstructive airway disease, Hepatic failure.

Dosage

Dextromoramide (Tartrate)'s dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
15 mg	15 mg	—	IM	As Required
20 mg	20 mg	—	Intra Rectal	As Required
0.178 mg/kg	0.178 mg/kg	—	PO	As Required
15 mg	15 mg	—	SC	As Required
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

Unknown2 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Dextromoramide (Tartrate) in overdosage may give rise to further complications which include Dependence .

Dextromoramide (Tartrate) produces potentially life-threatening effects which include Respiratory depression. Careful monitoring is needed with proper medical management.

Dextromoramide (Tartrate) is known to cause more or less tolerable side effects which are usually transient. These include Constipation , Dizziness, Giddiness, Nausea, SweatingX, Tachycardia, Vomiting .

Warnings / Precautions

Dextromoramide therapy should be commence with reduced dosage in the elderly and when there is evidence of impaired hepatic, renal or thyroid function, and should be discontinued gradually if dependence is suspected.

Available Brands

None recorded.

Storage Conditions

Dextromoramide (Tartrate) should be stored Tab, Inj(IV,SC),suppositry.

Drug Classification

1.2.2 — Opioid analgesics